Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer

ConclusionsThe serum UA level is a reliable biomarker for predicting the prognosis of patients undergoing immunotherapy for PLC, and might provide a basis for the individualized treatment of these patients. Dynamic monitoring of the serum UA level may compensate for the deficiency of the current liver cancer staging system.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research